Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 105 Cr.
- Current Price ₹ 130
- High / Low ₹ 148 / 83.6
- Stock P/E 19.5
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 35.42 | 35.58 | |
| 32.16 | 27.14 | |
| Operating Profit | 3.26 | 8.44 |
| OPM % | 9.20% | 23.72% |
| 0.34 | 0.31 | |
| Interest | 1.33 | 0.85 |
| Depreciation | 0.73 | 0.68 |
| Profit before tax | 1.54 | 7.22 |
| Tax % | 20.13% | 25.90% |
| 1.23 | 5.36 | |
| EPS in Rs | 24.60 | 107.20 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 336% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Equity Capital | ||
| Reserves | ||
| Total Liabilities | ||
| CWIP | ||
| Investments | ||
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Net Cash Flow | ||
| Free Cash Flow | ||
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | ||
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | ||
| Working Capital Days | ||
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Jan 2026 | |
|---|---|---|---|
| EBITDA Margin % ・Standalone data |
|
||
| PAT Margin % ・Standalone data |
|||
| Export Ready Products (New Registrations) Number ・Standalone data |
|||
| Domestic Turnover Share % ・Standalone data |
|||
| Export Turnover Share % ・Standalone data |
|||
| Land Size Square Meters ・Standalone data |
|||
| Number of Developed Formulations (Portfolio) Number ・Standalone data |
|||
| Own Brand Export Share in Revenue % ・Standalone data |
|||
| Total Construction Area (Manufacturing Facility) Square Meters ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
23 April 2026 - Curis Lifesciences says Regulation 27(2) and 24A reports not applicable for FY2026; certificate attached.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
10 April 2026 - Regulation 74(5) compliance certificate for quarter and year ended 31 March 2026.
-
Resignation
31 March 2026 - Curis Lifesciences Limited has informed regarding Resignation of Dhruvi Shyam Kapadia as Independent Director of the company w.e.f. April 01, 2026.
-
Resignation of Independent director
31 March 2026 - CURIS LIFESCIENCES LIMITED has informed about Resignation of Independent director.
-
Resignation
31 March 2026 - Ms. Dhruvi Shyam Kapadia resigned as Independent Director effective 01.04.2026 due to increased commitments; no other material reasons.
Annual reports
No data available.
Concalls
-
Mar 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptPPT
-
Jan 2026TranscriptPPT
Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.